Rationale, discovery and clinical development of NEO-201

Philip M. Arlen and Maria Pia Morelli
Precision Biologics Inc, Bethesda, MD, USA; Women’s Malignancy Branch, National Cancer Institute, Bethesda, MD, USA

ARTICLE HISTORY Received 11 June 2019; Accepted 20 November 2019
KEYWORDS CEACAMs; immunotherapy; monoclonal antibody; NEO-201